Hot Topics | Published:

Antidepressant potential of metabotropic glutamate receptor mGlu2 and mGlu3 negative allosteric modulators

Neuropsychopharmacologyvolume 44pages214236 (2019) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015;66:509–23.

  2. 2.

    Joffe ME, Centanni SW, Jaramillo AA, Winder DG, Conn PJ. Metabotropic glutamate receptors in alcohol use disorder: physiology, plasticity, and promising pharmacotherapies. ACS Chem Neurosci. 2018. [Epub ahead of print].

  3. 3.

    Chaki S. mGlu2/3 receptor antagonists as novel antidepressants. Trends Pharmacol Sci. 2017;38:569–80.

  4. 4.

    Bollinger KA, Felts AS, Brassard CJ, Engers JL, Rodriguez AL, Weiner RL, et al. Design and synthesis of mGlu2 NAMs with improved potency and CNS penetration based on a truncated picolinamide core. ACS Med Chem Lett. 2017;8:919–24.

  5. 5.

    Engers JL, Bollinger KA, Weiner RL, Rodriguez AL, Long MF, Breiner MM, et al. Design and synthesis of N-Aryl phenoxyethoxy pyridinones as highly selective and CNS penetrant mGlu3 NAMs. ACS Med Chem Lett. 2017;8:925–30.

  6. 6.

    Joffe ME, Santiago CI, Engers JL, Lindsley CW, Conn PJ. Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function. Mol Psychiatry. 2017. [Epub ahead of print].

Download references


We would like to acknowledge Drs. Darryle Schoepp, Shigeyuki Chaki and Ronald Duman, for their work evaluating the preclinical antidepressant-like effects of mGlu2/3 antagonists. MEJ was supported by a postdoctoral fellowship through the Pharmaceutical Research and Manufacturers of America Foundation. PJC was supported by National Institutes of Health (NIH) grants R01MH062646 and R37NS031373. PJC has been funded by NIH, AstraZeneca, Bristol-Myers Squibb, Michael J. Fox Foundation, Dystonia Medical Research Foundation, CHDI Foundation and Thome Memorial Foundation. Over the past 3 years, he has served on the Scientific Advisory Boards for Michael J. Fox Foundation, Stanley Center for Psychiatric Research Broad Institute, Karuna Pharmaceuticals, Lieber Institute for Brain Development, Clinical Mechanism and Proof of Concept Consortium, and Neurobiology Foundation for Schizophrenia and Bipolar Disorder.

Author information


  1. Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA

    • Max E. Joffe
    •  & P. Jeffrey Conn
  2. Vanderbilt Center for Neuroscience Drug Discovery, Nashville, TN, 37232, USA

    • Max E. Joffe
    •  & P. Jeffrey Conn
  3. Vanderbilt Center for Addiction Research, Nashville, TN, 37232, USA

    • Max E. Joffe
    •  & P. Jeffrey Conn


  1. Search for Max E. Joffe in:

  2. Search for P. Jeffrey Conn in:

Competing interests

PJC is an inventor on patents that protect different classes of metabotropic glutamate allosteric modulators and MEJ declares no competing interests.

Corresponding author

Correspondence to Max E. Joffe.

About this article

Publication history